Navigation Links
Tris Pharma's New Tool Fights Against Prescription Drug Abuse
Date:11/12/2008

SOUTH BRUNSWICK, N.J., Nov. 12 /PRNewswire/ -- Tris Pharma, a privately owned, specialty pharmaceutical company, today unveiled a key component in the nation's fight against opioid abuse. Its new drug delivery platform, NoBuse(TM), offers a technology by which companies can deliver effective pain relief or ADHD products that are nearly impervious to abuse.

In the United States, narcotic pain relievers have fueled a dangerous epidemic. One in five teens has abused a prescription pain medication(1) and emergency room visits associated with these drugs have increased 163 percent since 1995(2). The situation has created barriers to access for patients suffering from real pain: Doctors are more reticent to prescribe opioids, and regulators have refused to allow new analgesics on the market unless they have the highest forms of abuse deterrence measures in place.

But Tris Pharma's NoBuse(TM) technology allows companies to provide pain relief responsibly. "In the current environment where opioid abuse has become such a problem, companies must first consider safeguarding their drugs if they want to reach patients in need," says Ketan Mehta, CEO and Founder of Tris Pharma. "There's no reason for patients to suffer needlessly when NoBuse(TM) provides such an effective option for abuse prevention."

There is a perception that conventional sustained release formulations are less prone to abuse then immediate-release formulations. However, users can easily extract the full 12-24 hour dose from existing sustained-release preparations for immediate consumption and then snort, swallow, or inject it- all of which provides users a "high" and which can be extremely dangerous when larger than intended doses are taken.

The NoBuse(TM) delivery system is engineered to prevent abuse on a physical level without the need for additional ingredients. NoBuse(TM) employs a technique where the drug is complexed to very fine polymeric particles and coated with a highly flexible non-breakable film resulting in particles that are extremely difficult to extract drug from-even after crushing the tablet or dissolving it in alcohol.

"Abuse of prescription drugs is a fast-growing problem-being able to limit this liability is a real benefit to society," says Thomas Newton, MD, Professor of Psychiatry at the Baylor College of Medicine. "Other methods can be breached-but the data for NoBuse(TM) shows that it is virtually impossible for abusers to get around. I also like the fact that the abuse deterrence is not contingent on the patient being forced to take added active ingredients such as the antagonist naloxone. The vast majority of patients aren't abusers and there is no reason for them to ingest an additional drug they don't need."

The technology works across a range of oral dosage forms including tablets, liquid suspensions, orally disintegrating tablets, and drug strips. It can also be used to formulate an immediate-release product with a built-in abuse deterrent. In doing so, Tris Pharma's NoBuse(TM) technology provides important value and a competitive advantage against competing delivery technologies.

About Tris Pharma, Inc.

Tris Pharma, Inc. is a specialty drug delivery technology company. Tris specializes in controlled release dosage forms for liquid, solid and orally disintegrating tablets; abuse-deterrent technology; and bioavailability enhancement of poorly absorbed drugs. Through its pharma partners, Tris has more than 30 products in development, submission or on market. Tris' research and manufacturing facilities are located in central New Jersey, USA. For more information, please visit http://www.trispharma.com

(1) Partnership for a Drug Free America

(2) "Prescription for Danger," produced by the Office of National Drug Control Policy, January 2008


'/>"/>
SOURCE Tris Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PharmaSmart International, Inc. Redefines Blood Pressure Management through Technology and Pharmacy Focused Patient Services
2. Pharmasset to Webcast an Investor Event from the AASLD Meeting
3. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
4. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
5. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
6. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
7. Pharmassets Underwriters Release Shares from Lock-Up
8. Second Annual Eye Ball Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology
9. Sperm Donor Fights for His Rights as a Father in U.S. Supreme Court
10. Compound in Red Wine Fights Ravages of Age
11. Experimental Drug Fights Multiple Sclerosis Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... the healthcare industry, made the 2017 Inc. 5000 with a three-year sales ... the nation’s fastest-growing private companies and comprises the most comprehensive look at America’s ...
(Date:8/23/2017)... Francisco, CA (PRWEB) , ... August 23, 2017 , ... ... proud to announce a new blog archive organized month-by-month. The new rotation of archived ... treatments. Local Bay Area residents searching information about hair transplantation can review details online ...
(Date:8/22/2017)... AREA, CA (PRWEB) , ... August 22, 2017 ... ... an accessible luxurious collection of unique masks and serums that perfectly fuse the ... skin care advancements, at the 2017 Indie Beauty Expo on August 23rd & ...
(Date:8/22/2017)... ... ... of the past six years, Lightning Labels has sent out a call for users of ... variety and creativity of their designs. Submissions this year were open from May 18 to ... announce the winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... , ... “Wilderness Voices”: a collection of poetry inspired by life on a ... of published author, Martha McKown, an ordained United Methodist minister with graduate degrees in ... when her older sisters studied High School literature. She loved the early English ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
(Date:8/3/2017)... 2017  Opioid addiction and other drugs of abuse, ... and threatening outcomes, were problems taken on directly as ... that support them, met this week. This according to ... drugs of abuse, procalcitonin and acute kidney injury were ... 69th meeting in San Diego, CA. ...
Breaking Medicine Technology: